Danielle Greenawalt
0000-0002-6297-0753
Publication & Citation Trends
Publications
69 total
Prognostic Significance and Biologic Associations of Senescence‐Associated Secretory Phenotype Biomarkers in Heart Failure PDF
Cited by 15
OpenAlex
Phase 1/2 Study of the Indoleamine 2,3-Dioxygenase 1 Inhibitor Linrodostat Mesylate Combined with Nivolumab or Nivolumab and Ipilimumab in Advanced Solid Tumors or Hematologic Malignancies
Cited by 12
OpenAlex
Bioinformatic Methods and Bridging of Assay Results for Reliable Tumor Mutational Burden Assessment in Non-Small-Cell Lung Cancer PDF
Cited by 55
OpenAlex
<i>STK11/LKB1</i> Mutations and PD-1 Inhibitor Resistance in <i>KRAS</i>-Mutant Lung Adenocarcinoma PDF
Cited by 1,568
OpenAlex
Circulating T Cell Subpopulations Correlate With Immune Responses at the Tumor Site and Clinical Response to PD1 Inhibition in Non-Small Cell Lung Cancer PDF
Cited by 124
OpenAlex
Abstract LB-127: From bench to bedside: Exploring OX40 receptor modulation in a phase 1/2a study of the OX40 costimulatory agonist BMS-986178 ± nivolumab (NIVO) or ipilimumab (IPI) in patients with advanced solid tumors
Cited by 12
OpenAlex
Comparative analysis of primary <i>versus</i> relapse/refractory DLBCL identifies shifts in mutation spectrum PDF
Cited by 33
OpenAlex
Abstract CT021: Tumor-associated immune cell PD-L1 expression and peripheral immune profiling: Analyses from CheckMate 141
Cited by 14
OpenAlex
Research Topics
Cancer Genomics and Diagnostics
(20)
Cancer Immunotherapy and Biomarkers
(17)
Tryptophan and brain disorders
(14)
Lung Cancer Treatments and Mutations
(13)
Radiomics and Machine Learning in Medical Imaging
(7)
Affiliations
Thiel College
Merck & Co., Inc., Rahway, NJ, USA (United States)
The Royal Melbourne Hospital
Emory University
Bristol-Myers Squibb (Germany)